Leading Korean pharmaceutical company selects clinivation for a multinational product development initiative.
NATICK, MA – January 31, 2013 – Clinivation, Inc. is pleased to announce today that Shin Poong Pharmaceutical Company has selected clinivation to advance an important multinational product development initiative.
Quotes & Commentary:
“It is an honor and my pleasure to support this important initiative, and I thank Chairman Yong-Taek Chang and Head of Global Research Jei-Man Ryu for their global vision and support,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
Supporting Resources:
For more information on the clinivation’s Technology-Enabled CRO Services, please visit the clinivation CRO Services homepage
About Shin Poong Pharmaceutical Company:
With operations in Korea, China, the Philippines, Vietnam, and Sudan, Shin Poong Pharmaceutical Co., Ltd. (Korea Stock Exchange (KRX): 019170) has established manufacturing and commercial partnerships with the world’s leading pharmaceutical companies, including GlaxoSmithKline, Taisho, AstraZeneca, Sanofi-Aventis, Eli Lilly, Pfizer, Merck, and others.
Shin Poong develops, manufactures, and sells pharmaceutical products in South Korea and internationally. It offers cardiovascular, anti-cancer, psychoneurotic, antirheumatic, and antihistamine drugs, as well as antibiotics, antiulcerants, anti-diabetics, antifungal and antiviral agents, benign prostatic hyperplasia, and trichogens. The company also synthesizes NSAID, cardiovascular, anti-ulcer, respiratory, anti-diabetic, anti-biotic, propulsive, anti-cancer, anti-arthritis, anti-spasmodic, and anti-helminthic APIs. In addition, it offers chemotherapeutics; hormones; contraceptive agents; vitamins and minerals; nutrition and dermatological products; and eye, ear, and mouth preparations, as well as neuro-muscular system, hematopoietic system, metabolism, alimentary system, genito-urinary system, and allergy and immune system APIs.
